Drug Trial Radar · NCT00230217
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Last checked: Nov 20, 2026Latest source record: Mar 30, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Mar 2004
Primary completion
Jul 2006
Study completion Jul 2006
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Sep 30, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center study with 2 arms. The primary objective is to assess the response to treatment with rasburicase in 2 populations of adult and pediatric patients with lymphoma/leukemia/solid tumor malignancies, those previously treated with a uricolytic agent, and those not previously treated with a uricolytic agent at their first relapse or refractory disease.
Conditions
- Tumors
- Hyperuricemia
- Tumor Lysis Syndrome
Interventions
Rasburicase (SR29142)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive response based on plasma uric acid levels.Time frame: up to 48 hours after last administration.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Alta Bates Comprehensive Cancer Center
Berkley, California
Rocky Mountain Cancer Center
Denver, Colorado
University of Florida Health Science Center at Jacksonville
Jacksonville, Florida
New York Medical College
Valhalla, New York
University of Oklahoma HSC
Oklahoma City, Oklahoma
University of Pennsylvania Health Systems
Philadelphia, Pennsylvania
Mary Babb Randolph Cancer Center
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.